It has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence to support its use in other cancers such as breast cancer.
Afatinib
Imatinib
Neratinib
Dasatinib
Capmatinib
Tucatinib
Ponatinib
Lapatinib